CoronaryAtlas logo
CoronaryAtlas
Vitamin E
Pathway / Lipid retention & oxidation

Vitamin E

metabolite

Vitamin E depletion reflects oxidative stress during LDL modification and lipid-core pathogenesis in atherosclerotic plaque.

Pathway placement
Cascade stepLipid retention & oxidation
Confidencemedium
RationaleAntioxidant; counters lipid oxidation in subendothelial retention.
Druggability
Not assessed (no mapped human gene target).

Type I vs non-Type I discrimination

ScoresIndeterminate
R — rupture / Type-I
—
C — non-Type-I
21
A — assay feasibility
42
E — evidence strength
95
T1DI (composite)
19
Specificity differential (R−C)-5.8
Non-Type-I axis panel
Does this marker also move in each non-Type-I setting? mag 0–3; higher means less Type-I-specific. n/a = no evidence retrieved, which is not the same as no change.
2sepsis / systemic inflammationn/a
2anemia / acute blood lossmag 0
2hypovolemia / dehydrationmag 0
2tachyarrhythmiamag 2
2hypoxemia / respiratory failuremag 0
2hypertensive emergencymag 0
2high-demand / peri-operative stressmag 0
3sudden cardiac deathn/a
4aPCI-related periproceduralmag 1
4bstent thrombosisn/a
4cin-stent restenosisn/a
5CABG-relatedmag 2
Coverage: 8/12 axes with evidence
Tier: deep-scored (abstract-extracted) · 13 supporting references. See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum, plasma or urine
Collection tube
Serum separator (gold/red-top, SST) · Lithium heparin (green-top) · Sterile urine container
Method / principle
LC-MS/MS (targeted metabolomics) or enzymatic colorimetric where available
Reagent / substrate
Stable-isotope-labeled internal standard (MS); or enzyme-coupled Trinder reagent
Platform
LC-MS/MS; some automated chemistry
Turnaround · availability
Send-out / research · Specialized / research

Literature evidence(1)

Clinical trials(1)